FDA Expands Risankizumab Label in Psoriatic Disease
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The US food and drug administration has expanded the label for risankizumab, a treatment for psoriatic disease. This expansion indicates a broader approved use for the medication. The details of the expanded label have not been specified beyond its relation to psoriatic disease.